In addition, among 600 NSCLC patients, deleterious mutations in the DNA methyltransferase 3A (DNMT3A) gene has been found to be the most significant alteration enriched in ICI responders versus nonresponders [41], and DNMT3A loss has been found to be associated with significantly higher ORR, (50% vs. 20.5%, P < 0.001), longer mPFS (9.2 vs. 2.9 months, HR 0.60, P < 0.01), and mOS (23.1 s 12.1 months, HR 0.59, P = 0.01) among DNMT3AMUT compared to DNMT3AWT NSCLCs [41]. This evidence concerns the gene DNMT3A and non-small cell lung carcinoma.